NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,677 | +3.5% | 28,000 | 0.0% | 0.01% | +16.7% |
Q2 2023 | $16,106 | +19304.8% | 28,000 | -76.3% | 0.01% | -81.5% |
Q1 2023 | $83 | -68.9% | 118,000 | 0.0% | 0.06% | -65.6% |
Q4 2022 | $267 | -99.9% | 118,000 | -7.8% | 0.19% | -34.6% |
Q3 2022 | $410,000 | -15.6% | 128,000 | 0.0% | 0.29% | -18.4% |
Q2 2022 | $486,000 | -29.6% | 128,000 | 0.0% | 0.35% | -28.8% |
Q1 2022 | $690,000 | -48.9% | 128,000 | +28.0% | 0.50% | -42.9% |
Q4 2021 | $1,351,000 | +4.5% | 100,000 | +38.9% | 0.87% | -1.0% |
Q3 2021 | $1,293,000 | +4.6% | 72,000 | 0.0% | 0.88% | +19.1% |
Q2 2021 | $1,236,000 | -32.8% | 72,000 | -21.7% | 0.74% | -32.3% |
Q1 2021 | $1,840,000 | +444.4% | 92,000 | +868.4% | 1.09% | +430.1% |
Q2 2019 | $338,000 | +6.0% | 9,500 | 0.0% | 0.21% | +3.0% |
Q1 2019 | $319,000 | +2.2% | 9,500 | 0.0% | 0.20% | -32.2% |
Q4 2018 | $312,000 | -46.1% | 9,500 | 0.0% | 0.30% | -21.1% |
Q3 2018 | $579,000 | +24.8% | 9,500 | 0.0% | 0.37% | +18.7% |
Q2 2018 | $464,000 | – | 9,500 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |